Dutch Criteria for Familial Hypercholesterolemia (FH)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۳۰ • واحد: mmol/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Unlikely FH0–2
- Possible FH3–5
- Probable FH6–7
- Definite FH8–15
The Dutch Criteria for Familial Hypercholesterolemia (FH) calculates evaluating glycemic control, metabolic decompensation severity, and long-term endocrine risks. Key inputs include ldl cholesterol mmol. Scores guide titrating insulin infusion protocols, managing fluid-electrolyte resuscitation, and long-term risk reduction. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Diagnoses familial hypercholesterolemia (FH) based on clinical, genetic, and family history using the Dutch Lipid Clinic Network (DLCN) point-based scoring system. Provides stratification into possible, probable, or definite FH categories.
Clinical Indication
The Dutch Criteria for Familial Hypercholesterolemia (FH) is indicated for bedside clinical practice to support Diagnoses familial hypercholesterolemia (FH) based on clinical, genetic, and family history using the Dutch Lipid Clinic Network (DLCN) point-based scoring system. Provides stratification into possible, probable, or definite FH categories.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with diabetes mellitus, diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state, thyroid storm, or adrenal crisis. Clinical application is indicated across Endocrinology clinics, inpatient metabolic services, and acute diabetes care units.
Limitations & Contraindications
Severe hyperglycemia lowers measured serum sodium; corrected sodium equations must guide intravenous fluid selection.
Clinical Pearls & Action Plan
Serial monitoring of serum electrolytes, potassium kinetics, venous pH, and anion gap is mandatory during acute metabolic crisis management. Guideline pearl: Widely recommended by international guidelines including ESC/EAS and NLA recommendations..
Points awarded for: LDL cholesterol levels (1-8 points based on level), tendon xanthomas (6 points), corneal arcus <45 years (4 points), family history of elevated LDL (1 point), family history of premature CHD (1 point), personal premature CHD (2 points), personal premature CVD (1 point), positive DNA analysis (8 points). Scoring: 0-2 points = Unlikely FH, 3-5 points = Possible FH, 6-7 points = Probable FH, ≥8 points = Definite FH.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| ldl_cholesterol_mmol | float | Yes | LDL cholesterol level in mmol/L(mmol/L) |
| tendon_xanthomas | string | Yes | Presence of tendon xanthomas (Achilles tendon or dorsum of hand) |
| corneal_arcus | string | Yes | Corneal arcus in patient <45 years old |
| family_history_ldl | string | Yes | Family history of LDL cholesterol >4.9 mmol/L (190 mg/dL) in adult first-degree relative or >4.0 mmol/L (155 mg/dL) in child/sibling <18 years |
| family_history_chd | string | Yes | Family history of premature coronary heart disease (CHD) in first-degree relative (men <55 years, women <60 years) |
| personal_chd | string | Yes | Personal history of premature coronary heart disease (men <55 years, women <60 years) |
| personal_cvd | string | Yes | Personal history of premature cerebral or peripheral vascular disease (men <55 years, women <60 years) |
| dna_analysis | string | Yes | DNA analysis results: functional mutation in LDLR, APOB, or PCSK9 gene |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Unlikely FH | FH unlikely |
| 3–5 | Possible FH | Possible familial hypercholesterolemia |
| 6–7 | Probable FH | Probable familial hypercholesterolemia |
| 8–15 | Definite FH | Definite familial hypercholesterolemia |
Evidence-Based References (EBM)
- The diagnosis and management of familial hypercholesterolaemia. Dutch Health Care Insurance Board. 1999. Available from: https://www.lipidclinic.org/
- Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. doi: 10.1093/eurheartj/eht273.DOI: 10.1093/eurheartj/eht273
- Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-57. doi: 10.1093/eurheartj/ehu274.DOI: 10.1093/eurheartj/ehu274